Related Experiment Video
Updated: Jul 20, 2025
Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
Published on: October 4, 2021
Mesenchymal Stromal Cells-Derived Extracellular Vesicles as Potential Treatments for Osteoarthritis
Shunling Yuan1, Guangfeng Li2, Jinbo Zhang1,3
1School of Pharmacy, Naval Medical University, Shanghai 200433, China.
Abstract:
Osteoarthritis (OA) is a degenerative disease of the joints characterized by cartilage damage and severe pain. Despite various pharmacological and surgical interventions, current therapies fail to halt OA progression, leading to high morbidity and an economic burden. Thus, there is an urgent need for alternative therapeutic approaches that can effectively address the underlying pathophysiology of OA. Extracellular Vesicles (EVs) derived from mesenchymal stromal cells (MSCs) represent a new paradigm in OA treatment. MSC-EVs are small membranous particles released by MSCs during culture, both in vitro and in vivo. They possess regenerative properties and can attenuate inflammation, thereby promoting cartilage healing. Importantly, MSC-EVs have several advantages over MSCs as cell-based therapies, including lower risks of immune reactions and ethical issues. Researchers have recently explored different strategies, such as modifying EVs to enhance their delivery, targeting efficiency, and security, with promising results. This article reviews how MSC-EVs can help treat OA and how they might work. It also briefly discusses the benefits and challenges of using MSC-EVs and talks about the possibility of allogeneic and autologous MSC-EVs for medical use.
Insights
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) offer a promising new treatment for osteoarthritis (OA). These cell-free therapies promote cartilage healing and reduce inflammation, addressing OA
Area of Science:
- Regenerative Medicine
- Biotechnology
- Orthopedics
Background:
- Osteoarthritis (OA) is a degenerative joint disease causing cartilage damage and pain, with current treatments failing to halt progression.
- Existing therapies for OA lack efficacy in addressing the disease's underlying pathophysiology, necessitating novel therapeutic strategies.
- There is a significant unmet need for treatments that can effectively manage OA's morbidity and economic impact.
Purpose of the Study:
- To review the therapeutic potential of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) for osteoarthritis (OA) treatment.
- To elucidate the mechanisms by which MSC-EVs exert their therapeutic effects in OA.
- To discuss the advantages, challenges, and future prospects of MSC-EVs in OA therapy, including allogeneic and autologous applications.
Main Methods:
- Review of current scientific literature on MSC-EVs and their application in OA.
- Analysis of the regenerative and anti-inflammatory properties of MSC-EVs.
- Exploration of strategies to enhance MSC-EV delivery, targeting, and safety.
- Discussion of the comparative benefits of MSC-EVs over cell-based therapies.
Main Results:
- MSC-EVs demonstrate regenerative potential and can attenuate inflammation, promoting cartilage healing in OA.
- MSC-EVs offer advantages over MSCs, including reduced risks of immune reactions and ethical concerns.
- Ongoing research focuses on optimizing MSC-EVs for improved therapeutic efficacy and clinical translation.
Conclusions:
- MSC-EVs represent a promising cell-free therapeutic approach for osteoarthritis.
- Further research and development are crucial for harnessing the full potential of MSC-EVs in clinical OA management.
- The use of both allogeneic and autologous MSC-EVs warrants further investigation for medical applications.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...